Mark Penfold

Title: Innovator Mark Penfold: Advancements in Therapeutic Antibodies and Chemokine Inhibitors

Introduction

Mark Penfold, an inventive force located in Mountain View, CA, has made significant contributions to the field of biomedicine with his impressive portfolio of three patents. His pioneering work focuses on antibodies and bicyclic compounds that play critical roles in treating viral diseases, showcasing his commitment to advancing medical science.

Latest Patents

Mark's latest patents include two innovative inventions:

1. **Antibodies that bind CXCR7 epitopes** - This patent describes antibodies that specifically bind to CXCR7 epitopes, along with methods for identifying modulators of CXCR7, showcasing the potential for targeted therapeutic interventions.

2. **Bicyclic compounds as inhibitors of chemokine binding to US28** - This invention presents methods for treating cytomegalovirus (CMV) or related diseases using novel bicyclic compounds. These compounds consist of specific heteroaryl groups, combined with various substituents that enhance their therapeutic efficacy.

Career Highlights

Mark is currently associated with Chemocentryx, Inc., a company known for its innovative approach to drug development targeting systemic diseases. His role emphasizes cutting-edge research and the application of biological insights to create life-saving therapies.

Collaborations

During his career, Mark has worked alongside notable colleagues such as Brian E. McMaster and Thomas J. Schall. Together, they have fostered a collaborative environment that promotes innovation and accelerates the pathway from laboratory discoveries to practical treatments.

Conclusion

Mark Penfold stands out as a prominent inventor whose work in therapeutic antibodies and chemokine inhibitors has the potential to revolutionize treatment approaches for viral diseases. His ongoing contributions at Chemocentryx, Inc. continue to inspire advancements in biomedical research and innovation.